CN Patent

CN109988104B — 山奈酚与异烟酰胺共晶物及制备方法和其药物组合物与用途

Assigned to Institute of Materia Medica of CAMS and PUMC · Expires 2021-12-07 · 4y expired

What this patent protects

本发明公开了山奈酚与异烟酰胺共晶物及制备方法和其组合物与用途。具体而言，本发明公开了一种以山奈酚(如式a)为药物活性成分，异烟酰胺(如式b)为共晶配体的新山奈酚与异烟酰胺共晶物；山奈酚与异烟酰胺共晶物的制备方法；山奈酚与异烟酰胺共晶物作为药物活性成分在制备防治防癌、抗癌、抗炎、抗氧化、抗菌或抗病毒药物中的应用。

USPTO Abstract

本发明公开了山奈酚与异烟酰胺共晶物及制备方法和其组合物与用途。具体而言，本发明公开了一种以山奈酚(如式a)为药物活性成分，异烟酰胺(如式b)为共晶配体的新山奈酚与异烟酰胺共晶物；山奈酚与异烟酰胺共晶物的制备方法；山奈酚与异烟酰胺共晶物作为药物活性成分在制备防治防癌、抗癌、抗炎、抗氧化、抗菌或抗病毒药物中的应用。

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: CN109988104B
Jurisdiction: CN
Classification: —
Expires: 2021-12-07
Drug substance claim: No
Drug product claim: No
Assignee: Institute of Materia Medica of CAMS and PUMC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.